AI assistant
Sending…
Celldex Therapeutics, Inc. — Director's Dealing 2018
Jun 15, 2018
31801_dirs_2018-06-15_6e72fff1-8c07-42ca-94b8-49cf3bd93bd3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2018-06-13
Reporting Person: Crowley Elizabeth (Sr. VP &CPDO)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-06-13 | Incentive Stock Option (right to buy) | $.6011 | A | 300000 | Acquired | 2028-06-13 | Common Stock (300000) | Direct |
Footnotes
F1: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan.
F2: 25% vest on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
More from Celldex Therapeutics, Inc.
Interim / Quarterly Report
2026
May 7
Regulatory Filings
2026
May 7
Major Shareholding Notification
2026
May 6
Major Shareholding Notification
2026
Apr 29
Annual Report
2026
Apr 29
Proxy Solicitation & Information Statement
2026
Apr 29
Regulatory Filings
2026
Apr 2
Regulatory Filings
2026
Apr 2
Regulatory Filings
2026
Apr 1
Major Shareholding Notification
2026
Mar 26